Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATYR PHARMA, INC.

(LIFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ATyr Pharma : Says Lead Treatment Candidate Effective in Lung Disease Trial; Shares Soar

09/13/2021 | 12:18pm EST


ę MT Newswires 2021
All news about ATYR PHARMA, INC.
11/15ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/12ATYR PHARMA INC Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/12ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/11HC Wainwright Adjusts aTyr Pharma's Price Target to $11 from $18, Keeps Buy Rating
MT
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update - Form 8..
PU
11/10ATYR PHARMA : Q3 Earnings Snapshot
AQ
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
AQ
11/10ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
11/09ATyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, A..
AQ
11/09ATyr Pharma, Inc. Presents Research Demonstrating Effects of Novel NRP2-Targeting Antib..
CI
More news
Analyst Recommendations on ATYR PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 2,52 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,49x
Yield 2021 -
Capitalization 224 M 224 M -
Capi. / Sales 2021 89,0x
Capi. / Sales 2022 53,1x
Nbr of Employees 42
Free-Float 97,7%
Chart ATYR PHARMA, INC.
Duration : Period :
aTyr Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATYR PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,06 $
Average target price 18,50 $
Spread / Average Target 130%
EPS Revisions
Managers and Directors
Sanjay S. Shukla President, Chief Executive Officer & Director
Jill M. Broadfoot Chief Financial Officer
John K. Clarke Chairman
Leslie Nangle Vice President-Research
Paul R. Schimmel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATYR PHARMA, INC.107.73%224
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431